This study is a Phase 2, randomized, double-blind, placebo controlled, pilot study designed to evaluate the efficacy and safety of PRM-151 administered through Week 24 to subjects with IPF.
A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
PRM-151 is an anti-fibrotic immunomodulator being developed for treatment of fibrotic diseases.
Idiopathic Pulmonary Fibrosis
Open to people ages 40–80
Has IPF satisfying the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT)diagnostic criteria (Raghu, Collard et al. 2011). In the absence of a surgical lung biopsy, HRCT must be "consistent with "usual interstitial pneumonia" (UIP) defined as meeting either criteria A, B, and C, or criteria A and C, or criteria B and C below:
Is unable to refrain from use of the following:
© The Regents of the University of California